Navigation Links
Astellas to Review Strategic Business Alternatives for Prosidion Subsidiary
Date:1/10/2011

obal category leader in urology, immunology & infectious diseases, neuroscience, DM complications & metabolic diseases and oncology. For more information on Astellas Pharma Inc., please visit our website at http://www.astellas.com/en.

About Prosidion

Prosidion Ltd. (a subsidiary of Astellas Pharma Inc.) is a biopharmaceutical company, focused on discovering, developing and commercializing innovative molecular targeted therapies addressing major unmet medical needs in type 2 diabetes and obesity. The company's biological research is focused on neuroendocrine control of body weight and glycaemia. This combined with special expertise in the area of designed multiple ligands is geared to deliver novel, innovative first- or best-in-class therapies for type 2 diabetes and obesity. Prosidion is located in Oxford, in the UK close to a seat of international academic excellence. The company has state of the art facilities and fully integrated capabilities in research and development.

Statement of Cautionary Factors

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new us
'/>"/>

SOURCE Astellas Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reportlinker Adds Astellas Pharma Inc.: PharmaVitae Profile
2. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
3. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
4. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
5. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
6. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
7. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
8. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
9. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
10. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
11. Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... 2015  NanoSmart Pharmaceuticals, Inc., a private pharmaceutical ... Orphan Drug Designation from the Food and Drug ... uses NanoSmart,s proprietary drug delivery platform. The drug ... treatment of Ewing,s sarcoma, a rare type of ... Drug Designation on the basis of a plausible ...
(Date:7/30/2015)... 2015 Flexpoint Ford, a private equity firm ... announced that it has entered into a partnership with ... to form Kastle Therapeutics, LLC (Kastle).  The new company, ... on acquiring, developing and commercializing pharmaceuticals targeted toward diseases ... select therapies already approved for marketing, as well as ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
... 22, 2011 United Seating & Mobility (USM) ... transaction with Central Kentucky Mobility (CKM) to acquire and merge ... for Lexington, Louisville, as well as central, eastern and southern ... team strengthens our position within a core market for us ...
... WOONSOCKET, R.I., July 22, 2011 CVS Caremark Corporation ... conference call on Thursday, August 4, 2011, at 8:30 ... second quarter 2011 financial results. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ... will be broadcast simultaneously through the Investor Relations portion ...
Cached Medicine Technology:CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call 2
(Date:7/30/2015)... ... July 30, 2015 , ... The Clinical Data Interchange ... pleased to announce that data standards for clinical research in the areas of ... CDISC website . These three Therapeutic Area (TA) standards were developed per the ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... L-Alanyl-L-Glutamine for people on the go. With no water needed, the refreshing berry-flavored ... a simple way to get the natural ingredients that may help with body ...
(Date:7/30/2015)... ... ... Google recently announced that it will be disclosing any incidents involving its ... 8, 2015 article published by Nasdaq , the powerful tech company maintains that ... cars, which such industry players as Tesla CEO Elon Musk believe may very well ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Center,” to announce its position as one of Medicare’s top-rated care centers. ... members support the CMS rating system, which monitors health inspections, staffing, and ...
(Date:7/30/2015)... ... 2015 , ... Zejax is a New Way of Training ... , World renown body weight trainer, Paul Ziachik, announces today that he ... a person’s training capability. , The American College of Sports Medicine states that ...
Breaking Medicine News(10 mins):Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... , TUESDAY, March 1 (HealthDay News) -- For ... to relieve symptoms and result in major improvements in ... Up to 20 percent of women in their childbearing ... Not all fibroids cause symptoms, but some patients experience ...
... is a common problem in patients with chronic rhinosinusitis ... function, and quality of life (QOL), according to new ... Otolaryngology Head and Neck Surgery . ... and may have the following symptoms for 12 weeks ...
... 1, 2011) Endoscopic removal of pre-cancerous cells ... recommended rather than surveillance, according to a new ... Esophagus," published by the American Gastroenterological Association (AGA) ... Gastroenterology , the official journal of the ...
... Lymph node dissection, the current standard surgical treatment for ... screen-detected early stage cases , according to a study published ... Oncology (JTO), the official journal of the International Association ... nodal involvement is very low in early-stage cancers with a ...
... and Opportunistic Infections is taking place at the Hynes ... 2. Day two of this major HIV/AIDS research conference ... the National Institute of Allergy and Infectious Diseases (NIAID), ... HIV/TB Co-Infection , Diane Havlir, M.D., of the ...
... hundred years ago are being used in the development of ... time old bones have been used in this way. ... latest computer modelling techniques developed at the University of Leeds, ... With Engineering and Physical Sciences Research Council (EPSRC) funding, ...
Cached Medicine News:Health News:Uterine Fibroid Treatments Seem to Boost Quality of Life 2Health News:Effects of depression on quality of life improvement after endoscopic sinus surgery 2Health News:Watchful waiting no longer recommended for some high-risk Barrett's esophagus patients 2Health News:Watchful waiting no longer recommended for some high-risk Barrett's esophagus patients 3Health News:Lymph node dissection is not essential in small screen-detected lung cancers, new research shows 2Health News:CROI -- Day 2: Selected highlights of NIH-supported research 2Health News:CROI -- Day 2: Selected highlights of NIH-supported research 3Health News:CROI -- Day 2: Selected highlights of NIH-supported research 4Health News:Learning from old bones to treat modern back pain 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: